MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?

por Burton, S, Brown, G, Daniels, I R, Norman, A R, Mason, B, Cunningham, D
Publicado 2006

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

por Maisey, N R, Norman, A R, Hill, A, Massey, A, Oates, J, Cunningham, D
Publicado 2005

Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer

por Parker, C C, Norman, A R, Huddart, R A, Horwich, A, Dearnaley, D P
Publicado 2002

Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials

por Smith, N J, Bees, N, Barbachano, Y, Norman, A R, Swift, R I, Brown, G
Publicado 2007

The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract

por Formica, V, Wotherspoon, A, Cunningham, D, Norman, A R, Sirohi, B, Oates, J, Chong, G
Publicado 2007

Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil

por Tebbutt, N C, Norman, A R, Cunningham, D, Allen, M, Chau, I, Oates, J, Hill, M
Publicado 2003

Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status

por Watkins, D J, Chau, I, Cunningham, D, Mudan, S S, Karanjia, N, Brown, G, Ashley, S, Norman, A R, Gillbanks, A
Publicado 2010

Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas.

por Schneider, H. J., Sampson, S. A., Cunningham, D., Norman, A. R., Andreyev, H. J., Tilsed, J. V., Clarke, P. A.
Publicado 1997

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma

por Ng, M, Waters, J, Cunningham, D, Chau, I, Horwich, A, Hill, M, Norman, A R, Wotherspoon, A, Catovsky, D
Publicado 2005

Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer

por Rao, S, Cunningham, D, Price, T, Hill, M E, Ross, P J, Tebbutt, N, Norman, A R, Oates, J, Shellito, P
Publicado 2004

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan

por Chong, G, Dickson, J L B, Cunningham, D, Norman, A R, Rao, S, Hill, M E, Price, T J, Oates, J, Tebbutt, N
Publicado 2005

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer

por Rao, S, Cunningham, D, Hawkins, R E, Hill, M E, Smith, D, Daniel, F, Ross, P J, Oates, J, Norman, A R
Publicado 2005

Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?

por Chau, I, Jones, R, Cunningham, D, Wotherspoon, A, Maisey, N, Norman, A R, Jain, P, Bishop, L, Horwich, A, Catovsky, D
Publicado 2003

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with...

por Sumpter, K, Harper-Wynne, C, Cunningham, D, Rao, S, Tebbutt, N, Norman, A R, Ward, C, Iveson, T, Nicolson, M, Hickish, T, Hill, M, Oates, J
Publicado 2005

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer

por Saini, A, Norman, A R, Cunningham, D, Chau, I, Hill, M, Tait, D, Hickish, T, Iveson, T, Lofts, F, Jodrell, D, Ross, P J, Oates, J
Publicado 2003

Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with i...

por Chau, I, Norman, A R, Cunningham, D, Waters, J S, Topham, C, Middleton, G, Hill, M, Ross, P J, Katopodis, R, Stewart, G, Oates, J R
Publicado 2004

Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer

por Chau, I, Allen, M, Cunningham, D, Tait, D, Brown, G, Hill, M, Sumpter, K, Rhodes, A, Wotherspoon, A, Norman, A R, Hill, A, Massey, A, Prior, Y
Publicado 2003

Rapid access multidisciplinary lymph node diagnostic clinic: analysis of 550 patients

por Chau, I, Kelleher, M T, Cunningham, D, Norman, A R, Wotherspoon, A, Trott, P, Rhys-Evans, P, Rovere, G Querci Della, Brown, G, Allen, M, Waters, J S, Haque, S, Murray, T, Bishop, L
Publicado 2003

TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer

por Knight, J F, Shepherd, C J, Rizzo, S, Brewer, D, Jhavar, S, Dodson, A R, Cooper, C S, Eeles, R, Falconer, A, Kovacs, G, Garrett, M D, Norman, A R, Shipley, J, Hudson, D L
Publicado 2008

High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone

por O'Sullivan, J M, McCready, V R, Flux, G, Norman, A R, Buffa, F M, Chittenden, S, Guy, M, Pomeroy, K, Cook, G, Gadd, J, Treleaven, J, Al-Deen, A, Horwich, A, Huddart, R A, Dearnaley, D P
Publicado 2002